Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry. However, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. In this study, the investigators will identify Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital. Then, Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets \[MSK-IMPACT\]) will be identified in the GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. Finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. This study will elucidate important ancestry differences between Asian and Caucasian lung adenocarcinoma patients.
Study Type
OBSERVATIONAL
Enrollment
450
Oncoprint of somatic mutations
Association between genomic features and race
Time frame: July 2021
Copy number variations (CNVs)
CNVs analysis by race
Time frame: July 2021
Mutational signatures
Analysis of mutational signatures by race
Time frame: August 2021
Oncogenic pathways
Analysis of oncogenic pathways by race
Time frame: September 2021
Therapeutic actionability
Analysis of actionable alterations by race
Time frame: October 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.